U.S. markets close in 2 hours 9 minutes
  • S&P 500

    4,078.31
    -73.79 (-1.78%)
     
  • Dow 30

    33,765.82
    -503.34 (-1.47%)
     
  • Nasdaq

    13,076.77
    -312.65 (-2.34%)
     
  • Russell 2000

    2,171.29
    -35.70 (-1.62%)
     
  • Crude Oil

    66.35
    +1.07 (+1.64%)
     
  • Gold

    1,824.30
    -11.80 (-0.64%)
     
  • Silver

    27.29
    -0.38 (-1.36%)
     
  • EUR/USD

    1.2077
    -0.0075 (-0.62%)
     
  • 10-Yr Bond

    1.6770
    +0.0530 (+3.26%)
     
  • GBP/USD

    1.4064
    -0.0080 (-0.57%)
     
  • USD/JPY

    109.5700
    +0.9500 (+0.87%)
     
  • BTC-USD

    54,863.71
    -1,504.92 (-2.67%)
     
  • CMC Crypto 200

    1,481.94
    -81.89 (-5.24%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

Here's Why You Should Retain Equifax (EFX) in Your Portfolio

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Equifax Inc.’s EFX shares have charted a solid trajectory in recent times, appreciating a massive 66.5% over the past year, ahead of the industry’s gain of 58.2%.

The company has an impressive Growth Score of A. This style score condenses all the essential metrics from a company’s financial statements to get a true sense of quality and sustainability of its growth.

Equifax has an expected long-term earnings per share (three to five years) growth rate of 13.1%. Its revenues are expected to increase 7.8% in 2021 and 6% in 2022, year over year.

Factors That Auger Well

Equifax is benefiting from a solid product portfolio and clear understanding of the sectors it serves. Customers find considerable significance in the company’s offerings as they use the credit information and related analytical services and data to process applications for new credit cards, automobile loans, home and equity loans, and other consumer loans.

We believe synergies from acquisitions, in addition to continued general consumer credit activity, product innovation, initiatives to foster enterprise growth, and efficient business executions, will continue to boost Equifax’s revenues over the long run. Revenues have shown decent growth rates in the past few years, having grown at a CAGR of 5.6% from 2016 to 2020. The top line improved 23.5% year over year in the fourth quarter of 2020.

Debt Woes Stay

Equifax’s total debt at the end of fourth-quarter 2020 was $3.28 billion, flat sequentially. The company’s cash and cash equivalent of $1.68 billion at the end of the quarter was well below this debt level, underscoring that the company doesn’t have enough cash to meet this debt burden. The cash level, however, can meet the short-term debt of $1.1 billion.

Zacks Rank and Stocks to Consider

WEX currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader Zacks Business Services sector are The Interpublic Group of Companies IPG, Cross Country Healthcare CCRN and Charles River Associates CRAI, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The long-term expected earnings per share (three to five years) growth rate for Interpublic, Cross Country Healthcare and Charles River is pegged at 2.4%, 12% and 13%, respectively.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

AccessZacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Equifax, Inc. (EFX) : Free Stock Analysis Report

Charles River Associates (CRAI) : Free Stock Analysis Report

Interpublic Group of Companies, Inc. The (IPG) : Free Stock Analysis Report

Cross Country Healthcare, Inc. (CCRN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research